Home/Pipeline/Tadliq® (Tadalafil Oral Suspension)

Tadliq® (Tadalafil Oral Suspension)

Pulmonary Arterial Hypertension

ApprovedMarketed

Key Facts

Indication

Pulmonary Arterial Hypertension

Phase

Approved

Status

Marketed

Company

CMP Pharma

About CMP Pharma

Founded in 1975, CMP Pharma is a legacy pharmaceutical company dedicated to creating customized oral liquid and topical formulations for patients underserved by traditional solid dosage forms, particularly in acute and long-term care settings. The company has achieved significant milestones with FDA approvals for novel liquid formulations of established drugs, including Norliqva (amlodipine), Tadliq (tadalafil), and CaroSpir (spironolactone). CMP's strategy centers on identifying niche therapeutic markets, developing high-value alternative dosage forms, and manufacturing products at its facility in Farmville, North Carolina, for distribution to hospitals, long-term care facilities, and retail channels.

View full company profile

Therapeutic Areas

Cardiovascular Hypertension Pulmonary Arterial Hypertension Heart Failure Hyperkalemia Tuberculosis Dermatology Metabolic Disorders

Other Pulmonary Arterial Hypertension Drugs

Drug	Company	Phase	Status
JTV-161	Akros Pharma	Phase1	Active
PROPHET	Occlutech	Pilot	Active
Soft Mist Inhaler for PAH (with unnamed Pharma Partner)	Resyca	Not Disclosed	Active
LTSE-2578	Structure Therapeutics	Phase 1	Active
Tyvaso DPI®	MannKind Corp	Approved	Commercial (Partner: United Therapeutics)
F230	Gyre Therapeutics	Not Specified	Evaluated